TimesSquare Capital Management LLC Buys New Position in CeriBell, Inc. (NASDAQ:CBLL)

TimesSquare Capital Management LLC purchased a new stake in shares of CeriBell, Inc. (NASDAQ:CBLL - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 536,829 shares of the company's stock, valued at approximately $10,312,000. TimesSquare Capital Management LLC owned 1.50% of CeriBell as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. FMR LLC purchased a new position in shares of CeriBell during the fourth quarter valued at approximately $128,120,000. TPG GP A LLC bought a new position in shares of CeriBell during the fourth quarter worth $102,677,000. Red Tree Management LLC purchased a new stake in CeriBell during the fourth quarter valued at $57,083,000. Yu Fan purchased a new stake in CeriBell during the fourth quarter valued at $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd purchased a new stake in shares of CeriBell in the fourth quarter valued at $28,160,000.

Analyst Ratings Changes

A number of analysts have recently weighed in on CBLL shares. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price target on the stock. BTIG Research assumed coverage on shares of CeriBell in a research report on Tuesday, June 24th. They set a "buy" rating and a $30.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $32.14.

CeriBell Stock Down 1.1%

NASDAQ CBLL traded down $0.18 during trading hours on Thursday, hitting $15.62. The company had a trading volume of 192,367 shares, compared to its average volume of 289,542. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.36 and a quick ratio of 16.81. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The business has a fifty day simple moving average of $17.52 and a 200-day simple moving average of $19.48.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. The company had revenue of $20.49 million during the quarter, compared to analysts' expectations of $19.30 million. Research analysts predict that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Insider Buying and Selling

In other CeriBell news, Director Rebecca B. Robertson sold 11,188 shares of the business's stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $17.85, for a total value of $199,705.80. Following the transaction, the director owned 10,042 shares of the company's stock, valued at approximately $179,249.70. The trade was a 52.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Xingjuan Chao sold 25,000 shares of CeriBell stock in a transaction on Monday, July 7th. The stock was sold at an average price of $17.70, for a total transaction of $442,500.00. Following the sale, the chief executive officer directly owned 776,022 shares of the company's stock, valued at $13,735,589.40. This represents a 3.12% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 132,633 shares of company stock worth $2,252,081. 20.10% of the stock is currently owned by company insiders.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.